FDA approves Cyramza for stomach cancer

08 May 2014 3:26 PM | Lori Aubrey (Administrator)

On April 21, 2014, the US Food and Drug Administration (FDA) approved CYRAMZA™(ramucirumab). CYRAMZA as a single agent is indicated for the treatment of patients with advanced or metastatic gastric or gastroesophageal junction adenocarcinoma with disease progression on or after prior fluoropyrimidine- or platinum-containing chemotherapy.




Northern New England Clinical Oncology Society
P.O. Box 643
Sandown, NH 03873-0643
Telephone (603) 887-1948

This website brought to you by:

Powered by Wild Apricot Membership Software